지에프씨생명과학
Financials
Valuation Metrics
지에프씨생명과학's Market Cap is ₩225B. At end of 2025 it was ₩756B. Ranked #2200 of 2,405 in KR market (top 91%), #1440 of 1,627 on KOSDAQ (top 89%), #65 of 68 in Financial Services (top 96%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 22.47B KRW | KR#2,200/2,405 Sec#65/68 |
| Revenue | 17.71B KRW | KR#2,167/2,405 Sec#56/68 |
| Net Income | 555.4M KRW | KR#1,516/2,405 Sec#57/68 |
| Total Assets | 33.83B KRW | KR#2,302/2,405 Sec#61/68 |
| Net Assets | 23.80B KRW | KR#2,236/2,405 Sec#61/68 |
| Employees | 80 | KR#1,805/2,405 Sec#39/68 |
| Value | ||
| P/E | 40.46x | KR#1,387/2,405 Sec#56/68 |
| P/B | 0.94x | KR#1,482/2,405 Sec#44/68 |
| P/S | 1.27x | KR#1,591/2,405 Sec#37/68 |
| EV/EBITDA | 56.92x | KR#1,387/2,405 Sec#53/68 |
| FCF Yield | -28.23% | KR—/2,405 Sec—/68 |
| Profitability | ||
| ROE | 2.33% | KR#1,376/2,405 Sec#55/68 |
| ROA | 1.64% | KR#1,279/2,405 Sec#36/68 |
| Op. Margin | 2.18% | KR#1,355/2,405 Sec#54/68 |
| Revenue Growth | 5.42% | KR#1,167/2,405 Sec#42/68 |
| Financial Health | ||
| Debt Ratio | 42.16% | KR#832/2,405 Sec#20/68 |
| Total Debt | 6.98B KRW | KR#1,718/2,405 Sec#42/68 |
| FCF | -6.34B KRW | KR#1,559/2,405 Sec#31/68 |
| Cash | 7.47B KRW | KR#1,841/2,405 Sec#54/68 |
| Current Ratio | 5.60x | KR#242/2,405 Sec#3/68 |
| Net Debt/EBITDA | -1.26x | KR#326/2,405 Sec#14/68 |
| Performance | ||
| 1Y Return | -74.13% | KR#2,309/2,405 Sec#64/68 |
| 1M Return | -23.69% | KR#2,043/2,405 Sec#57/68 |
| From 52W High | -77.55% | KR#2,247/2,405 Sec#62/68 |
| 1Y MDD | -77.31% | KR#2,221/2,405 Sec#63/68 |
| Trading | ||
| Volume | 4,651 shares | KR#2,120/2,405 Sec#59/68 |
| Trading Value | 19.4M KRW | KR#2,100/2,405 Sec#62/68 |
| Foreign Own. | 2.91% | KR#1,312/2,405 Sec#36/68 |
| Per Share | ||
| EPS | 104 KRW | KR#1,416/2,405 Sec#55/68 |
| BPS | 4,469 KRW | KR#1,584/2,405 Sec#47/68 |
Company Info
GFC Life Science, established in 2002, listed on KONEX in 2022 and transferred to KOSDAQ in 2025. The company specializes in developing and producing cosmetic biomaterials using skin microbiome and exosome technologies, alongside providing efficacy testing and advertising substantiation data for functional cosmetics. Leveraging a library of over 2,000 strains, more than 80 patented microorganisms, and patented exosome isolation and purification technology, it is actively developing skin booster products and pursuing global market expansion. GFC Life Science is headquartered in Hwaseong-si, Gyeonggi-do.